CLINICAL_TRIALS
trial_result
· 2021-03-10
Clinical Trial Update: Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis [Phase 3]
Summary
Phase 3 safety extension study of tanezumab given subcutaneous injection in osteoarthritis was terminated; results posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Osteoarthritis | Phase 3 | Status: TERMINATED | Results posted: 2021-03-10